Resource Library
The resource library contains information about substance use, treatment and prevention. The information is provided by Delaware Substance Abuse Mental Health, Opioid Response Providers Network, Health Management Associates and other sources. Providers can search information by topics, settings, and file types simply by using the drop-down menus.
Section
- General Resources
- Planning Documents
- Sample Workflows
- Patient Treatment Agreements
- Confidentiality Considerations for Primary Care
- Clinical Tools
- Contingency Management Modules
- Sample Protocols and Policies
- Patient Education
- EHR Resources
- Quality Assurance and Peer Review Tools
- Delaware Specific Resources
- Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
- Considerations for Treating OUD in Patients with HIV or Hepatitis
- Harm Reduction
- GPRA
- MAT
- Naloxone Narcan
- Payors-Funding
- Referrals
- Reporting
- Delaware State Opioid Response (SOR) Initiative Information for Providers
Topic
- ASAM LOC Determination
- Behavioral Health
- Buprenorphine
- Clinical Workflow Support
- COVID-19
- Dual Diagnosis/Co-Occuring
- Harm Reduction/Contingency Mgmt
- Health Information Technology
- Level of Care Determination
- Medication Assisted Treatment (MAT)
- Medicaid
- Medication for Opioid Use Disorder (MOUD)
- Medication for other substance use disorders
- Motivational Interviewing
- Naloxone/Narcan
- Neonatal Abstinance Syndrome (NAS)
- Payors/Funding
- Pharmacology/Prescribing
- Pregnancy & Pre/Post Partum
- Privacy/42 CFR Part 2
- Process Improvement
- Referrals
- Regulations - State/Federal/County
- Screening and/or Assessment
- Self/family care or supports
- Stigma Abatement
- Substance/Stimulant/Opiod Use Disorder
- Systems - Federal/State/County
- Telehealth
- Toxicology
- Withdrawl/Withdrawl Management
Setting
- All
- Behavioral Health
- Community-Based
- Drug Court
- FQHC
- Hospital
- Institutes of Mental Disease (IMD)
- OBOT
- Outpatient
- Patient/Family/Friends
- Pharmacy
- Primary Care
- Residential
Type
- Best Practice/Policy/Guideline/Procedure
- Clinical Care Guidelines
- Data/Statistics
- Delaware specific resources
- FAQ
- FAQ/General Information/Fact Sheet
- General Information/Fact Sheet
- Issue Brief/Reference Guide
- Literature Review
- Newsletter
- Report
- Supplemental Materials
- Templates
- Toolkit
- Training
- Training Guide
- Training Slides
Format:
- Word
- Excel
- Link
- PowerPoint
- Video
Reset filters
Sort by Date Modified
Sort Alphabetically
Total Resources:
Naloxone Access Training
February 8, 2024
This presentation is designed to train participants on how to identify and properly respond to an opioid overdose. Naloxone (Narcan) is one of the most important tools available to reverse the effects of an opioid overdose
Naloxone Narcan
Naloxone/Narcan
Substance/Stimulant/Opiod Use Disorder
Community-Based
Training
SOR 3.0 Tier Award Program Year 2 Screening, Brief Intervention and Referral to Treatment (SBIRT) Kickoff Webinar: PowerPoint
January 24, 2024
PowerPoint – This TAP Tier 3.A Kickoff webinar slide deck contains an overview of the TAP program as well as foundational content about the SBIRT Model, including a review of the key components of SBIRT, its evidence base, and common workflows.
Delaware State Opioid Response (SOR) Initiative Information for Providers
Level of Care Determination
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
All
Supplemental Materials
SOR 3.0 Tier Award Program Year 2 Screening, Brief Intervention and Referral to Treatment (SBIRT) Kickoff Webinar: Recording
January 24, 2024
Recording – This TAP Tier 3.A Kickoff webinar offered participants an overview of the TAP program as well as foundational content about the SBIRT Model, including a review of the key components of SBIRT, its evidence base, and common workflows.
Delaware State Opioid Response (SOR) Initiative Information for Providers
Level of Care Determination
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
All
Supplemental Materials
Contingency Management for Healthcare Settings: Clinical Supervisors
October 19, 2023
(2.5 hours; asynchronous)
Contingency Management Modules
Contingency Management for Healthcare Settings: Decision Makers
October 19, 2023
(1 hour; asynchronous)
Contingency Management Modules
Contingency Management for Healthcare Settings: Direct-Care Staff
October 19, 2023
(2 hours; asynchronous)
Contingency Management Modules
Motivational Incentives: Positive Reinforcers to Enhance Successful Treatment Outcomes
October 19, 2023
(5 hours; asynchronous)
Motivational Incentives: Positive Reinforcers to Enhance Successful Treatment Outcomes is 5-hour, self-paced course, designed to assist clinical supervisors in designing and customizing a Motivational Incentives program within the context of their community-based treatment organization.
Contingency Management Modules
2021 Adult Core Set
May 1, 2023
2021 Core Set of Adult Health Care Quality Measures for Medicaid (Adult Core Set)
Reporting
Behavioral Health
Medicaid
Regulations - State/Federal/County
Behavioral Health
Outpatient
Data/Statistics
CSAT GPRA Training Revised
May 1, 2023
Center for Substance Abuse Treatment (CSAT) Government Performance and Results Act (GPRA) Training Power Point saved in pdf form.
GPRA
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Systems - Federal/State/County
OBOT
Outpatient
Training
Clinical Opiate Withdrawal Scale
May 1, 2023
This tool can be used in both inpatient and outpatient settings to reproducibly rate common signs and symptoms of opiate withdrawal and monitor these symptoms over time.
Clinical Tools
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Withdrawl/Withdrawl Management
FQHC
OBOT
Outpatient
Primary Care
Residential
Issue Brief/Reference Guide
Intranasal Naloxone Rapidly Occupies Brain Mu-Opioid Receptors in Human Subjects
May 1, 2023
This study provides initial characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone administration to healthy volunteers in the absence of a competing opioid agonist.
Naloxone Narcan
Medication for Opioid Use Disorder (MOUD)
Naloxone/Narcan
Withdrawl/Withdrawl Management
Community-Based
Outpatient
Literature Review
Enhancing Motivation for Change in SUD Treatment (SAMHSA TIP 35)
May 1, 2023
Motivation for change is a key component in addressing substance misuse. This Treatment Improvement Protocol (TIP) reflects a fundamental rethinking of the concept of motivation as a dynamic process, not a static client trait.
General Resources
Behavioral Health
Motivational Interviewing
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
OBOT
Outpatient
Best Practice/Policy/Guideline/Procedure
Supportive Treatment for Addiction and Recovery (STAR): Policy and Procedure at Heartland Alliance Health
May 1, 2023
Policies and Procedures for Medications for Addiction Treatment at Heartland Alliance Health - Updated October 2019
Sample Workflows
Dual Diagnosis/Co-Occuring
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
Toxicology
Behavioral Health
FQHC
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Evidence Based Resource Guide on Treatment of Stimulant Use Disorder
May 1, 2023
The goal of this guide is to review the literature on treating stimulant use disorders, distill the research into recommendations for practice, and provide examples of how practitioners use these practices in their programs.
General Resources
Harm Reduction/Contingency Mgmt
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
OBOT
Outpatient
Best Practice/Policy/Guideline/Procedure
SAMHSA Sample Treatment Agreement XR Naltrexone
May 1, 2023
Naltrexone practice treatment agreement and other documentation are clear about policies regarding number of doses in each prescription, refills, and rules on “lost” prescriptions.
Patient Treatment Agreements
Naloxone/Narcan
Pharmacology/Prescribing
Process Improvement
OBOT
Outpatient
Disclosure of Substance Use Disorder Patient Records
May 1, 2023
This fact sheet focuses on helping health care providers determine how Part 2 applies to them by depicting scenarios they might encounter when caring for patients.
Confidentiality Considerations for Primary Care
Health Information Technology
Privacy/42 CFR Part 2
Regulations - State/Federal/County
Behavioral Health
FQHC
Primary Care
Best Practice/Policy/Guideline/Procedure
Overcoming Care Team Barriers to Providing OUD Care
May 1, 2023
This toolkit provides proven strategies, best practices, and tools used by organizations to expand the capability of primary care teams in commercial and safety-net sectors to confidently and willingly provide SUD services.
Planning Documents
Clinical Workflow Support
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
FQHC
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Guide to Medication for Treating Alcohol Use Disorder
May 1, 2023
This guide reviews current evidence on the effectiveness of available medications for the treatment of alcohol use
disorders and developed guidance for the use of medications in clinical practice.
General Resources
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
Withdrawl/Withdrawl Management
Behavioral Health
Outpatient
Primary Care
Issue Brief/Reference Guide
MAT Models in Primary Care
May 1, 2023
This Technical Brief describes promising and innovative MAT models of care in primary care settings, describes barriers to MAT implementation, summarizes the evidence available on MAT models of care in primary care settings, identifies gaps in the evidence base, and guides future research.
General Resources
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
FQHC
OBOT
Primary Care
Best Practice/Policy/Guideline/Procedure
DSM-5 Criteria for Diagnosis of OUD
May 1, 2023
In order to confirm a diagnosis of OUD, at least two of the following items on this checklist should be observed within a 12-month period.
Clinical Tools
Behavioral Health
Dual Diagnosis/Co-Occuring
Screening and/or Assessment
Behavioral Health
OBOT
Best Practice/Policy/Guideline/Procedure
ASAM Sample Diversion Policy
May 1, 2023
These procedures will establish the steps to be taken to prevent, monitor, and respond to misuse and diversion of buprenorphine.
Sample Protocols and Policies
Clinical Workflow Support
Level of Care Determination
Substance/Stimulant/Opiod Use Disorder
Outpatient
Residential
Best Practice/Policy/Guideline/Procedure
Facts for Families and Friends
May 1, 2023
Resource guide/ factsheet explaining MOUD to families.
Patient Education
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Outpatient
Patient/Family/Friends
FAQ/General Information/Fact Sheet
Heartland Sample Medical Visit Quick Texts
May 1, 2023
Heartland sample medical visit quick texts for patient engagement and retention.
EHR Resources
Behavioral Health
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
Telehealth
Community-Based
FQHC
Outpatient
Primary Care
Supplemental Materials
Accelerating Opioid Safety in Ambulatory Care
May 1, 2023
This toolkit summarizes best practices and contains links to resources and tools that you can adapt as you build or test changes for your organization and patients.
Quality Assurance and Peer Review Tools
Medication for Opioid Use Disorder (MOUD)
Naloxone/Narcan
Substance/Stimulant/Opiod Use Disorder
Community-Based
FQHC
Hospital
Outpatient
Primary Care
Toolkit
Consensus Statement on Obstetric Care for Women with OUD
May 1, 2023
Comprehensive adoption of this patient safety bundle has the potential to foster a compassionate, nonjudgmental approach to health care delivery, optimize patient safety, and ultimately, change the course of an epidemic.
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Substance/Stimulant/Opiod Use Disorder
Withdrawl/Withdrawl Management
All
Behavioral Health
FQHC
Hospital
OBOT
Outpatient
Primary Care
Residential
Literature Review
Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings
May 1, 2023
The objective of this narrative review is to describe strategies for the integration of evidence-based harm reduction principles and interventions into outpatient, primary care–based OUD treatment settings.
Harm Reduction
Harm Reduction/Contingency Mgmt
Substance/Stimulant/Opiod Use Disorder
All
Behavioral Health
Outpatient
Literature Review
Medications for Opioid Use Disorder Save Lives
May 1, 2023
This independent review provides candid and critical comments that will assist the National Academies of Sciences, Engineering, and Medicine in making each published report as sound as possible and to ensure that it meets the institutional standards for quality, objectivity, evidence, and responsiveness.
Behavioral Health
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
OBOT
Outpatient
Best Practice/Policy/Guideline/Procedure
SAMHSA TIP 63 – Executive Summary Medications for Opioid Use Disorder
May 1, 2023
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
SAMHSA TIP 63 – Medications for Opioid Use Disorder
May 1, 2023
This TIP reviews three FDA-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Primary Care
Best Practice/Policy/Guideline/Procedure
Standard Framework for Levels of Integrated Care
May 1, 2023
Table of the Six Levels of Collaboration/Integration provided by SAMHSA-HRSA CENTER FOR INTEGRATED HEALTH SOLUTIONS
Behavioral Health
Clinical Workflow Support
Substance/Stimulant/Opiod Use Disorder
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Waiver Application
May 1, 2023
Learn how to become a Buprenorphine waivered (X-Waiver) practitioner to treat opioid use disorder (OUD).
General Resources
Buprenorphine
Pharmacology/Prescribing
Regulations - State/Federal/County
Substance/Stimulant/Opiod Use Disorder
FQHC
Hospital
Institutes of Mental Disease (IMD)
OBOT
Outpatient
Primary Care
General Information/Fact Sheet
Primary Care Based Models for OUD
May 1, 2023
This article summarizes findings of a technical report for the Agency for Healthcare Research and Quality describing MAT models of care for
OUD, based on a literature review and interviews with key informants in the field.
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Systems - Federal/State/County
FQHC
OBOT
Outpatient
Primary Care
Literature Review
MAT Implementation Checklist
May 1, 2023
This checklist provides policymakers, state and local officials, and other community stakeholders key questions to consider before
engaging in efforts to increase access to medication assisted treatment (MAT) for addictions in their communities.
Planning Documents
Clinical Workflow Support
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Ten Elements of Success
May 1, 2023
This fact sheet provides Ten Elements of Success for Primary Care Buprenorphine programs.
Planning Documents
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Outpatient
Primary Care
FAQ/General Information/Fact Sheet
Paying for MAT in Community Health Centers
May 1, 2023
To integrate medication-assisted treatment (MAT) into primary care, health centers must engage providers and staff, design the clinical model, determine how to identify patients, redesign workflow, and promote cross-discipline coordination.
Planning Documents
Medication Assisted Treatment (MAT)
Medicaid
Medication for Opioid Use Disorder (MOUD)
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
FQHC
Primary Care
General Information/Fact Sheet
Documentation & Charge Capture Process: MAT
May 1, 2023
Primary care services can also play a significant role in the success of the MAT Program by screening patients for potential substance use disorders. Thus, a process flow between primary care and the MAT Program
as it pertains to screening, brief intervention, and referral for treatment is outlined.
Planning Documents
Clinical Workflow Support
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Outpatient
Primary Care
Report
Business Case for MAT Services
May 1, 2023
This document is a business plan for MAT.
Planning Documents
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
FQHC
Hospital
Outpatient
Primary Care
Report
MSHC Sample MAT Workflow Referral
May 1, 2023
Mile Square Health Center (MSHC) Main Medication Assisted Treatment (MAT) for Opioid Use Disorder (OUD) Transition Workflow
Sample Workflows
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
Outpatient
Best Practice/Policy/Guideline/Procedure
MSHC MAT Sample Workflow Program Design – Patient Phases
May 1, 2023
The purpose of the MAT program is to provide quality treatment for individuals living with Substance Use Disorder.
Sample Workflows
Behavioral Health
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
Outpatient
Best Practice/Policy/Guideline/Procedure
Buprenorphine Home Initiation vs Office Initiation Considerations
May 1, 2023
This document outlines considerations that can help practices choose whether to offer buprenorphine office initiation, home
initiation, or both.
Sample Workflows
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Community-Based
FQHC
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
SAMHSA Decision Tree Behavioral Health Referrals
May 1, 2023
Flow chart for Referring Patients Who Receive OUD Pharmacotherapy to Behavioral Health Therapies.
Sample Workflows
Behavioral Health
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Primary Care
Best Practice/Policy/Guideline/Procedure
MOUD Initiation and Follow Up Sample Workflows
May 1, 2023
Sample Workflows from Health Center MOUD intake and initiation.
Sample Workflows
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
FQHC
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Buprenorphine Initiation Sample Workflow from HAH
May 1, 2023
Buprenorphine Treatment Workflow
Sample Workflows
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
FQHC
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Medication Assisted Recovery for OUD Transition Workflow
May 1, 2023
Workflows for Integrated Behavioral Health Services and OUD Treatment.
Sample Workflows
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
FQHC
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
PCSS Sample Treatment Agreement Buprenorphine
May 1, 2023
Buprenorphine/Naloxone Treatment Agreement
Patient Treatment Agreements
Buprenorphine
Pharmacology/Prescribing
Process Improvement
OBOT
Outpatient
Clinical Care Guidelines
Heartland Sample Treatment Agreement Buprenorphine
May 1, 2023
Policies and Procedures for Medications for Addiction Treatment at Heartland Alliance Health Updated October 2019.
Patient Treatment Agreements
Buprenorphine
Pharmacology/Prescribing
Process Improvement
OBOT
Outpatient
Pharmacy
Clinical Care Guidelines
Heartland Sample Treatment Agreement XR Naltrexone
May 1, 2023
Supportive Treatment for Addiction and Recovery (STAR) Policies and Procedures for Medications for Addiction Treatment at Heartland Alliance Health Updated October 2019
Patient Treatment Agreements
Naloxone/Narcan
Pharmacology/Prescribing
Process Improvement
OBOT
Outpatient
Pharmacy
Clinical Care Guidelines
MSHC Sample Treatment Agreement Buprenorphine
May 1, 2023
Medication Assisted Treatment (MAT) Agreement FOR Buprenorphine
Patient Treatment Agreements
Buprenorphine
Pharmacology/Prescribing
Process Improvement
OBOT
Outpatient
Pharmacy
Clinical Care Guidelines
How do I Exchange Part 2 Data
May 1, 2023
Disclosure of Substance Use Disorder Patient Records
Confidentiality Considerations for Primary Care
Health Information Technology
Privacy/42 CFR Part 2
Regulations - State/Federal/County
Behavioral Health
FQHC
Primary Care
Best Practice/Policy/Guideline/Procedure
Elica Sample Combined Intake and Consent Form
May 1, 2023
Elica Sample Combined Intake and Consent Form
Confidentiality Considerations for Primary Care
Privacy/42 CFR Part 2
Referrals
Regulations - State/Federal/County
Behavioral Health
FQHC
Primary Care
Templates
New Hampshire Sample Release of Information
May 1, 2023
This compendium of best practice recommendations and resources has been developed to provide guidance and support to initiate and expand MAT services for OUDs for patient populations in a variety of service settings as requested by health care and behavioral health professionals.
Confidentiality Considerations for Primary Care
Privacy/42 CFR Part 2
Regulations - State/Federal/County
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
FQHC
Primary Care
Templates
OUD Medication Comparison
May 1, 2023
Medications for Opioid Use Disorder For Healthcare and Addiction Professionals, Policymakers, Patients, and Families UPDATED 2020
Clinical Tools
Harm Reduction/Contingency Mgmt
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Naloxone/Narcan
Withdrawl/Withdrawl Management
OBOT
Outpatient
Clinical Care Guidelines
Buprenorphine Appropriate Use
May 1, 2023
Medications for Opioid Use Disorder For Healthcare and Addiction Professionals, Policymakers, Patients, and Families UPDATED 2020.
Clinical Tools
Buprenorphine
Harm Reduction/Contingency Mgmt
Medication for Opioid Use Disorder (MOUD)
Withdrawl/Withdrawl Management
OBOT
Outpatient
Clinical Care Guidelines
Use of Drug Testing
May 1, 2023
The purpose of the Appropriate Use of Drug Testing in Clinical Addiction Medicine is to provide guidance about the effective use of drug testing in the identification, diagnosis, treatment, and promotion of recovery for patients with, or at risk for, addiction.
Clinical Tools
Harm Reduction/Contingency Mgmt
Screening and/or Assessment
Toxicology
Withdrawl/Withdrawl Management
FQHC
OBOT
Outpatient
Primary Care
Clinical Care Guidelines
Patient Counseling Tool for XR Naltrexone
May 1, 2023
Resources Related to Medications for Opioid Use Disorder - TIP 63.
Clinical Tools
Naloxone/Narcan
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
OBOT
Outpatient
Supplemental Materials
Reducing Naltrexone Injection Site Reactions
May 1, 2023
TREATMENT IMPROVEMENT PROTOCOL TIP 63 - Key Techniques for Reducing Injection Site Reactions.
Clinical Tools
Naloxone/Narcan
Substance/Stimulant/Opiod Use Disorder
Withdrawl/Withdrawl Management
OBOT
Outpatient
Primary Care
Supplemental Materials
Opioid Use, Misuse, and Overdose in Women
May 1, 2023
This report was developed as part of an initiative supported by the U.S. Department of Health and Human Services (HHS) Office on Women’s Health (OWH) to examine the prevention, treatment, and recovery issues for women who misuse, have use disorders, and/or overdose on opioids.
Clinical Tools
Pregnancy & Pre/Post Partum
Substance/Stimulant/Opiod Use Disorder
Withdrawl/Withdrawl Management
FQHC
OBOT
Outpatient
Primary Care
Supplemental Materials
BMC Sample Urine Toxicology Policy
May 1, 2023
The purpose of these clinical guidelines is to provide detailed policies and protocols of the Office Based Addiction Treatment program for the use of buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations) in the treatment of substance use disorders at BMC.
Sample Protocols and Policies
Clinical Workflow Support
Substance/Stimulant/Opiod Use Disorder
Toxicology
Drug Court
Outpatient
Best Practice/Policy/Guideline/Procedure
Elements of an OBOT Diversion Control Plan
May 1, 2023
Provider Informational, Educational, and Decision-Making Tools
Sample Protocols and Policies
Harm Reduction/Contingency Mgmt
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
OBOT
Outpatient
FAQ/General Information/Fact Sheet
Guidance on Billing for OBOT
May 1, 2023
Prescriber Billing for Office-Based Treatment of Opioid Use Disorder guidelines.
Sample Protocols and Policies
Payors/Funding
Regulations - State/Federal/County
Substance/Stimulant/Opiod Use Disorder
OBOT
Primary Care
Best Practice/Policy/Guideline/Procedure
Heartland Sample Late Arrival Policy
May 1, 2023
Supportive Treatment for Addiction and Recovery (STAR) Policies and Procedures for Medications for Addiction Treatment at Heartland Alliance Health Updated October 2019 - Heartland Sample Late Arrival Policy.
Sample Protocols and Policies
Behavioral Health
Process Improvement
Self/family care or supports
Behavioral Health
Outpatient
Best Practice/Policy/Guideline/Procedure
Heartland Sample Referral Protocol
May 1, 2023
Supportive Treatment for Addiction and Recovery (STAR) Policies and Procedures for Medications for Addiction Treatment at Heartland Alliance Health Updated October 2019 - Heartland Sample Referral Protocol.
Sample Protocols and Policies
Clinical Workflow Support
Process Improvement
Referrals
Behavioral Health
Outpatient
Best Practice/Policy/Guideline/Procedure
Heartland Sample Urine Drug Testing
May 1, 2023
Supportive Treatment for Addiction and Recovery (STAR) Policies and Procedures for Medications for Addiction Treatment at Heartland Alliance Health Updated October 2019 - Heartland Sample Urine Drug Testing.
Sample Protocols and Policies
Clinical Workflow Support
Harm Reduction/Contingency Mgmt
Process Improvement
FQHC
Outpatient
Primary Care
Residential
Best Practice/Policy/Guideline/Procedure
How to Prepare for a DEA Inspection
May 1, 2023
The following document was prepared by the partner organizations of the Physicians’ Clinical
Support System-Buprenorphine. It provides background information regarding DEA inspection
procedures and suggestions on how buprenorphine waivered physicians can prepare for a DEA
inspection of their office-based practice.
Sample Protocols and Policies
Pharmacology/Prescribing
Process Improvement
Regulations - State/Federal/County
Outpatient
Pharmacy
MSHC Sample Policy Sanctions and Incentives
May 1, 2023
Sample policy MAT Program Sanctions and Incentives.
Sample Protocols and Policies
Harm Reduction/Contingency Mgmt
Process Improvement
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
FQHC
Outpatient
Primary Care
FAQ/General Information/Fact Sheet
SAMHSA Diversion Control Protocol
May 1, 2023
This template combines adaptations of diversion control strategies for OTPs described in the Federal Guidelines for Opioid Treatment Programs and adherence monitoring approaches that address diversion in SAMHSA’s Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder.
Sample Protocols and Policies
Medication Assisted Treatment (MAT)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
Outpatient
Pharmacy
Best Practice/Policy/Guideline/Procedure
Guide to Taking Suboxone
May 1, 2023
Guide to taking Suboxone/Buprenorphine
Patient Education
Buprenorphine
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Withdrawl/Withdrawl Management
Outpatient
Patient/Family/Friends
Best Practice/Policy/Guideline/Procedure
Starting Buprenorphine Outside of Clinics
May 1, 2023
Tool for Starting Buprenorphine Outside of Hospitals/Clinics
Patient Education
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Outpatient
Patient/Family/Friends
FAQ/General Information/Fact Sheet
Three Medication Comparison Guide
May 1, 2023
Lists of medications proven to lead to better recovery outcomes than other types of treatment.
Patient Education
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Outpatient
Patient/Family/Friends
FAQ/General Information/Fact Sheet
SAMHSA Sample Patient Goal Setting Form
May 1, 2023
Sample Provider Forms for patient goal setting.
EHR Resources
Behavioral Health
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Community-Based
Outpatient
General Information/Fact Sheet
Sample Behavioral Health Quick Text
May 1, 2023
Sample Behavioral Health intake for consideration of MAT program.
EHR Resources
Behavioral Health
Medication Assisted Treatment (MAT)
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Telehealth
Behavioral Health
Outpatient
General Information/Fact Sheet
Heartland Sample Peer Review Form
May 1, 2023
Sample HAR STAR Primary Care Peer Review�� form.
Quality Assurance and Peer Review Tools
Process Improvement
Screening and/or Assessment
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
Community-Based
Outpatient
Best Practice/Policy/Guideline/Procedure
MAT in Primary Care Capability Assessment
May 1, 2023
Use this document if you’d like to print out the assessment and have team members complete drafts separately before completing the final version together as a group. T
Quality Assurance and Peer Review Tools
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
FQHC
Primary Care
Supplemental Materials
New Hampshire Sample Quality Planning Tool
May 1, 2023
This compendium of best practice recommendations and resources has been developed to provide guidance and support to initiate and expand MAT services for OUDs for patient populations in a variety of service settings as
requested by health care and behavioral health professionals.
Quality Assurance and Peer Review Tools
Clinical Workflow Support
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
OBOT
Outpatient
Best Practice/Policy/Guideline/Procedure
Quality Measures for MAT in Primary Care
May 1, 2023
ADDICTION TREATMENT STARTS HERE: PRIMARY CARE (ATSH:PC) DATES, MEASURES AND DEFINITIONS (Updated 8.12.19).
Quality Assurance and Peer Review Tools
Clinical Workflow Support
Medication for Opioid Use Disorder (MOUD)
Process Improvement
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Primary Care
Data/Statistics
Sample Behavioral Health Program Peer Review Form
May 1, 2023
Sample Behavioral Health Program Peer Review Form 21.
Quality Assurance and Peer Review Tools
Behavioral Health
Screening and/or Assessment
Self/family care or supports
Behavioral Health
Outpatient
Supplemental Materials
Delaware Treatment Referral Network (DTRN) Overview
May 1, 2023
Delaware Treatment and Referral Network (DTRN) is a statewide, comprehensive referral network for behavioral health and substance use disorder treatment.
Delaware Specific Resources
Behavioral Health
Referrals
Substance/Stimulant/Opiod Use Disorder
Behavioral Health
Hospital
Outpatient
Primary Care
Residential
Delaware specific resources
Patient Factsheet – Intro to OUD Treatment during Pregnancy
April 29, 2023
Factsheet 1/4 of series - Opioid use disorder and pregnancy - Taking helpful steps for a healthy pregnancy
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Self/family care or supports
FQHC
Hospital
OBOT
Outpatient
Pharmacy
Primary Care
FAQ/General Information/Fact Sheet
Patient Factsheet – NAS Treatment
April 29, 2023
Factsheet 3/4 of series - Treating babies who were exposed to opioids before birth - Support for a new beginning
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Substance/Stimulant/Opiod Use Disorder
All
Community-Based
FQHC
Hospital
OBOT
Outpatient
Primary Care
Residential
FAQ/General Information/Fact Sheet
Patient Factsheet – OUD Treatment during Pregnancy
April 29, 2023
Factsheet 2/4 of series - Treating opioid use disorder during pregnancy - Getting the help and support you need from your healthcare professionals
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Medication for Opioid Use Disorder (MOUD)
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Self/family care or supports
Substance/Stimulant/Opiod Use Disorder
All
Community-Based
FQHC
OBOT
Outpatient
Patient/Family/Friends
Primary Care
Residential
FAQ/General Information/Fact Sheet
Patient Factsheet – OUD Treatment for Pregnant and Post-Natal Women
April 29, 2023
Factsheet 4/4 of series -- Good care for you and your baby while receiving opioid use disorder treatment - Steps for healthy growth and development.
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Medication for Opioid Use Disorder (MOUD)
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Substance/Stimulant/Opiod Use Disorder
All
Community-Based
FQHC
OBOT
Outpatient
Patient/Family/Friends
Primary Care
Residential
General Information/Fact Sheet
Summary of Literature on Treating Pregnant Women Parents and their Children
April 29, 2023
This article summarizes the literature review conducted using the RAND/University of California, Los Angeles Appropriateness Method
project completed by the US Department of Health and Human Services Substance Abuse and Mental Health Services Administration to obtain current evidence on treatment approaches.
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Medication for Opioid Use Disorder (MOUD)
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Primary Care
Clinical Care Guidelines
Treating Pregnant Women
April 29, 2023
Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants.
Considerations for Treating OUD in Pregnant Women, New Moms, and their Children
Medication for Opioid Use Disorder (MOUD)
Neonatal Abstinance Syndrome (NAS)
Pregnancy & Pre/Post Partum
Substance/Stimulant/Opiod Use Disorder
FQHC
Hospital
OBOT
Primary Care
Clinical Care Guidelines
Concurrent Treatment of HIV and OUD
April 29, 2023
Opioid Use Disorders in People Living with HIV/AIDS: A Review of Implications for Patient Outcomes, Drug Interactions, and Neurocognitive Disorders - This review describes the effects of prescription and non-prescription opioid use in PLWHA.
Considerations for Treating OUD in Patients with HIV or Hepatitis
Dual Diagnosis/Co-Occuring
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
FQHC
OBOT
Primary Care
Clinical Care Guidelines
Considerations for MAT in Patients with HCV+
April 29, 2023
Considerations for Medication for Addiction Treatment in HCV+ Patients document
Considerations for Treating OUD in Patients with HIV or Hepatitis
Dual Diagnosis/Co-Occuring
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
FQHC
Hospital
OBOT
Primary Care
Clinical Care Guidelines
Considerations for MAT in Patients with HIV
April 29, 2023
Considerations for Medication for Addiction Treatment in Patients with HIV form.
Considerations for Treating OUD in Patients with HIV or Hepatitis
Dual Diagnosis/Co-Occuring
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
FQHC
Hospital
OBOT
Pharmacy
Primary Care
Clinical Care Guidelines
CARES Anti-Stigma Language Guide
April 29, 2023
The following table, adapted from the National Institute on Drug Abuse’s Words Matter language guide, outlines appropriate language for discussing people who use drugs and related topics.
Harm Reduction
Behavioral Health
Harm Reduction/Contingency Mgmt
Stigma Abatement
All
Outpatient
Issue Brief/Reference Guide
Tier 1 Application
April 29, 2023
Delaware Opioid Response Provider Network Tier 1 Application Packet
Delaware State Opioid Response (SOR) Initiative Information for Providers
Medication for Opioid Use Disorder (MOUD)
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 1 Application Budget Template
April 29, 2023
Tier 1 Application Budget Template
Delaware State Opioid Response (SOR) Initiative Information for Providers
Medication for Opioid Use Disorder (MOUD)
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 1 Data Reporting Requirement
April 29, 2023
How to Calculate and Report your Monthly Tier 1 Reporting Measure
Delaware State Opioid Response (SOR) Initiative Information for Providers
Medication for Opioid Use Disorder (MOUD)
Screening and/or Assessment
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 2/3 Min Grant Solicitation
April 29, 2023
This mini-grant application is designed to fund Tier 2 and Tier 3 projects.
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 2/3 Min Grant Application
April 29, 2023
Tier Award Payment Program Tiers 2 & 3 Application
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 2/3 Mini Grant Budget Template
April 29, 2023
TIER 2/3 budget detail worksheet
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 2/3 Data Reporting Requirements
April 29, 2023
How to Submit Your Tier 2 and 3 Reporting Measures
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Frequently Asked Questions
April 29, 2023
Tier Award Payment (TAP) Frequently Asked Questions
Delaware State Opioid Response (SOR) Initiative Information for Providers
Medication for Opioid Use Disorder (MOUD)
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
FAQ
Infection Control Screening Form (Fillable)
April 29, 2023
Fillable Infection Control Screening Form
General Resources
COVID-19
Process Improvement
Regulations - State/Federal/County
All
Community-Based
FQHC
Hospital
Outpatient
Primary Care
Residential
Best Practice/Policy/Guideline/Procedure
CSAT Admin Survey
April 29, 2023
Best Practices CSAT Administrative Surveys Information Adapted from SPARS
GPRA
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Systems - Federal/State/County
OBOT
Outpatient
General Information/Fact Sheet
CSAT GPRA Tool Fillable PDF
April 29, 2023
CSAT GPRA Client Outcome Measures Tool - As part of this federal mandate, all SAMHSA grantees are required to collect and report performance data using approved measurement tools.
GPRA
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Systems - Federal/State/County
OBOT
Outpatient
Supplemental Materials
One Page FAQ for CSAT GPRA
April 29, 2023
One Page FAQ for the Center for Substance Abuse Treatment Government Performance and Results Act - updated January 2020.
GPRA
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Systems - Federal/State/County
OBOT
Outpatient
FAQ
SOR Fact Sheet
April 29, 2023
SOR Fact Sheet updated January 2020.
GPRA
Payors/Funding
Substance/Stimulant/Opiod Use Disorder
Systems - Federal/State/County
OBOT
Outpatient
General Information/Fact Sheet
MAT Implementation Checklist SAMHSA CIHS
April 29, 2023
This checklist provides policymakers, state and local officials, and other community stakeholders key questions to consider before
engaging in efforts to increase access to medication assisted treatment (MAT) for addictions in their communities.
MAT
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
OBOT
Outpatient
Supplemental Materials
Medication Brochure Guide
April 29, 2023
Medications for Opioid Use Disorder Guide to Using the Brochure
MAT
Buprenorphine
Medication Assisted Treatment (MAT)
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
FQHC
OBOT
Outpatient
Primary Care
Issue Brief/Reference Guide
OUD Medications
April 29, 2023
This brochure provides basic information for educational purposes. Speak with a healthcare professional to make
an informed decision that best fits your needs including learning the risks and benefits of all treatment options. Revised March 2020
MAT
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
FQHC
Hospital
OBOT
Outpatient
Primary Care
Supplemental Materials
Characterizing Fentanyl-Related Overdoses and Implications for Overdose Response
April 29, 2023
This study builds off of research characterizing fentanyl exposure to further explore the presentation of fentanyl use and related overdoses among people who use drugs.
Naloxone Narcan
Naloxone/Narcan
Toxicology
Withdrawl/Withdrawl Management
Community-Based
Outpatient
Literature Review
Cost of Opioid Overdose Education and Naloxone Distribution in NYC
April 29, 2023
OEND operating costs vary by program type and number of sites. Funders should consider that providing free naloxone to OEND programs does not cover full operating costs. Further exploration of cost effectiveness and program efficiency should be considered across different types of OEND settings.
Naloxone Narcan
Medication for Opioid Use Disorder (MOUD)
Neonatal Abstinance Syndrome (NAS)
Substance/Stimulant/Opiod Use Disorder
Community-Based
Outpatient
Literature Review
Naloxone POD Training Guide
April 29, 2023
Naloxone Point of Distribution (POD) Training Guide
Naloxone Narcan
Medication for Opioid Use Disorder (MOUD)
Naloxone/Narcan
Withdrawl/Withdrawl Management
Community-Based
Outpatient
Training Guide
Pilot Testing a Tool to Determine the Costs and Time Associated with Community Pharmacy-Based Administration of Injectable Naloxone
April 29, 2023
To pilot test a process to obtain a preliminary estimate of the total costs and time associated with community-pharmacist administered IN.
Naloxone Narcan
Medication for Opioid Use Disorder (MOUD)
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
Community-Based
Hospital
Literature Review
Treatment of Overdose in the Synthetic Opioid Era
April 29, 2023
The development of more effective reversal agents are described in this review is an essential component of a tripartite strategy (Volkow and Collins, 2017) to reduce the biopsychosocial impact of opioid misuse in the “synthetic era”.
Naloxone Narcan
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Naloxone/Narcan
Community-Based
Outpatient
Best Practice/Policy/Guideline/Procedure
State-Funded Services Policy Paper
April 29, 2023
This policy paper details the Department’s vision for the delivery of State-funded behavioral health, I/DD, and TBI services, as well as the continuation of critical “local health functions”3 under Behavioral Health I/DD Tailored Plans.
Payors-Funding
Payors/Funding
Regulations - State/Federal/County
Systems - Federal/State/County
Behavioral Health
Community-Based
Best Practice/Policy/Guideline/Procedure
Colorado Primary Care Specialty Care Compact
April 29, 2023
The purpose of this document is provide a framework for better communication and safe transition of care between primary care and specialty care providers.
Referrals
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Referrals
Substance/Stimulant/Opiod Use Disorder
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
Copy of AAFP Referral Tracking
April 29, 2023
Referral tracking spreadsheet that can be edited.
Referrals
Behavioral Health
Medication for Opioid Use Disorder (MOUD)
Referrals
Outpatient
Primary Care
Best Practice/Policy/Guideline/Procedure
CFRADM
April 29, 2023
Consumer Reporting Form - Admission Report
Reporting
Behavioral Health
Medicaid
Regulations - State/Federal/County
Behavioral Health
Outpatient
Data/Statistics
CFR Annual
April 29, 2023
Delaware Division of Substance Abuse And Mental Health - Annual Consumer Reporting form
Reporting
Behavioral Health
Medicaid
Regulations - State/Federal/County
Behavioral Health
Outpatient
Data/Statistics
CRFDIS
April 29, 2023
DSAMH CONSUMER REPORTING FORM - DISCHARGE REPORT
Reporting
Behavioral Health
Medicaid
Regulations - State/Federal/County
Behavioral Health
Outpatient
Data/Statistics
Tier 2/3 Mini Grant Implementation Work Plan Template
April 29, 2023
DSAMH SOR TAP Program Tier 2-3 Implementation Plan
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 2/3 Min Grant Resource Guide
April 29, 2023
DSAMH has created this resource guide to support the Delaware Opioid Response Provider Network in completing the Tier Award Program (TAP) Mini Grant Application for Tiers 2 and 3. This guide provides best practices, program examples, common metric samples that reflect the application target areas.
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
Tier 2/3 Data Reporting training Resource
April 29, 2023
Tier 2/3 Web-based survey training session -The purpose of the Tier 2/3 web-based survey is to collect data to measure the progress made by Tier 2/3 providers on their key performance indicators
Delaware State Opioid Response (SOR) Initiative Information for Providers
Buprenorphine
Medication for Opioid Use Disorder (MOUD)
Substance/Stimulant/Opiod Use Disorder
Hospital
Outpatient
Best Practice/Policy/Guideline/Procedure
DSAMH PPE Provider Guide
April 29, 2023
This document provides guidance on the proper use of PPE.
General Resources
Clinical Workflow Support
COVID-19
Regulations - State/Federal/County
All
Community-Based
FQHC
Outpatient
Primary Care
Residential
Best Practice/Policy/Guideline/Procedure
ASAM Drug Testing Pocket Guide
April 29, 2023
The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use
Clinical Tools
ASAM LOC Determination
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
Outpatient
Residential
Supplemental Materials
PMP User Guide
April 29, 2023
PMP AWARxE Requestor User Support Manual provides step-by-step instructions for healthcare professionals requesting data from the Delaware Monitoring Program (PMP) database
Delaware Specific Resources
Health Information Technology
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
FQHC
Hospital
Pharmacy
Primary Care
Best Practice/Policy/Guideline/Procedure
PMP Fact Sheet
April 29, 2023
Delaware Specific Resources
Health Information Technology
Pharmacology/Prescribing
Substance/Stimulant/Opiod Use Disorder
FQHC
Pharmacy
Primary Care
Best Practice/Policy/Guideline/Procedure
ORC Xylazine Information Bulletin
April 29, 2023
Information bulletin on the drug Xylazine. The front of the bulletin is to inform Delaware treatment providers, the back of the bulletin may be used by providers to engage in conversations with their patients/clients. This bulletin is NON-SENSETIVE and may be shared freely within your agencies and among your partners.
No results found.